Proof-of-Concept Research Demonstrates Patients Reliably Perform Remote Self-Sampling of Concerning Moles Using DermTech’s Non-Invasive Adhesive Skin Collection Kit Under Physician Supervision via Tel

LA JOLLA, CA, US - May 11, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that SKIN, the official journal of the National Society for Cutaneous Medicine, published proof-of-concept data demonstrating that patients are able to reliably perform remote self-sampling of concerning moles using the DermTech Pigmented Lesion Assay (the “DermTech PLA”) under physician supervision via telemedicine, enabling actionable molecular testing for accurate melanoma detection

The Melanoma Research Foundation Hosting Weekly Facebook Live ‘Ask a Dermatologist’ Sessions throughout Melanoma Awareness Month

LA JOLLA, CA, US - May 5, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech”) and the Melanoma Research Foundation (MRF) recognize Melanoma Awareness Month this May with an “Ask a Dermatologist” webinar series offered on MRF’s Facebook page every Thursday throughout the month to raise awareness of melanoma and educate around the dangers of the fastest growing and most deadly form of skin cancer

DermTech Announces Telemedicine Solution to Enable Remote Use of its Non-Invasive Adhesive Patch Test for Melanoma Detection

LA JOLLA, CA, US - Apr 30, 2020 - DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), today announced that its lead non-invasive melanoma detection test, the DermTech Pigmented Lesion Assay (the “DermTech PLA”), is now available for use by clinicians and their patients via telemedicine

Greenphire Enhances Its Participant Payment and Reimbursement Solution to Further Support Remote Clinical Trials

KING OF PRUSSIA, PA, UNITED STATES - May 11, 2020 - As the COVID-19 pandemic continues to limit movement all over the world, clinical trials have had to adapt by leveraging methodologies typically associated with hybrid or remote clinical trial designs

Rho Recognized with CRO Leadership Award from Leading Industry Publications

DURHAM, NC, US - May 11, 2020 - For Immediate ReleaseRho Recognized with CRO Leadership Award fromLeading Industry PublicationsResearch Triangle Park, NC - May 11, 2020 - Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, has been honored with a 2020 CRO Leadership Award by leading industry publications Life Science Leader and Clinical Leader for the third time

COVID-19 Pandemic to Heighten Market Prospects for Drug Delivery Systems: Market Set to Register Strong 7% Growth, Concludes Fact.MR

DUBLIN 2, IRELAND - May 11, 2020 - The ongoing COVID-19 pandemic is set to leverage the global drug delivery systems market, expanding at a CAGR of 7

Agendia Co-Founder and Chief Scientific Officer René Bernards, PhD Elected to the National Academy of Sciences

NEW YORK, NY, UNITED STATES - May 8, 2020 -

• Development of MammaPrint®,first FDA-cleared molecular diagnostic test for personalized treatment of breast cancer, considered a landmark achievement in breast cancer testing and treatment

Find the One-stop Bispecific Antibody Services and Products at Creative Biolabs

SHIRLEY, NY, UNITED STATES - May 11, 2020 - Bispecific antibody (BsAb) is a technology that has just been commercialized in the past ten years. However, its commercial prospect has already shown a bright outlook as BsAb has been considered a prospective drug for tumor and cancer treatment and a large number of projects in its research and development are underway

Spring Bank Pharmaceuticals Reports First Quarter 2020 Financial and Operational Results

HOPKINTON, MA, UNITED STATES - May 7, 2020 - Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the first quarter ended March 31, 2020 and provided an update on recent corporate and clinical development highlights

AI VIVO seeks collaboration partners to progress top-ranked COVID-19 therapeutic candidates

CAMBRIDGE, UK - May 7, 2020 -

• 41 of the candidate drugs from AI VIVO's top-ranked list for COVID-19 are now in clinical trials for COVID-19 by multiple groups globally
• Demonstrates the ability of AI VIVO's unique phenotypic drug discovery methodology to identify and rank therapeutic candidates
• AI VIVOselected other drugs as single and combinations from their top-ranked list and seeks partners with pharma companies and clinical trial investigators

CluePoints Covid-19 Support Benefits Over 200 Clinical Studies Directly Affected by the Pandemic

KING OF PRUSSIA, PA, US - May 7, 2020 - CluePoints, the premier provider of Risk-Based Quality Management (RBQM) and Data Quality Oversight Software for clinical trials, today announced that its recently launched complimentary COVID-19 risk assessment package and Data Surveillance solution is being utilized in over 200 ongoing studies that are directly affected by Covid-19

KCR’s Bryan Katz named in PM360’s ELITE 100

BOSTON, MA - May 7, 2020 - KCR, the international clinical development solutions provider, announced today that its Chief Commercial Officer, Bryan Katz, was honored by healthcare marketing industry trade magazine PM360  as one of their 2020 ELITE 100 award winners

Norway’s arctic university Tromsø installs MR Solutions’ high field, dry magnet, PET-MR imaging system

GUILDFORD, UNITED KINGDOM - May 7, 2020 - For use in advanced medical research into inflammation, oncology and nephritis the 7T PET-MR imaging system from MR Solutions provides a combination of PET and MRI images either simultaneously or separately

Covid-19 Volunteer Testing Network scaling up - delivering tests for GPs and care home workers

OXFORD, UK - May 7, 2020 -

• The Covid-19 Volunteer Testing Network is scaling up towards thousands of tests per day
• 6 labs around the country are now live with 20 more in the pipeline
• Local labs can deliver a fast-turnaround for their nearby GPs and care home workers
• One lab in the network identified an outbreak in a community care provider with asymptomatic staff testing positive
• Underscores the vital importance of regular screening of healthcare workers who might otherwise unknowingly be spreading the virus

Halfpenny Technologies, an Accumen Company, Launches COVID-19 Test Capacity and Routing Network Across 870 U.S. Hospitals to Accelerate Diagnostic Testing

PHOENIX, AZ - May 6, 2020 - Halfpenny Technologies, Inc., a wholly owned subsidiary of Accumen, Inc., today announced the launch of its COVID-19 Test Capacity and Routing Network (The “Network”)

Widening Application Scope and COVID-19 Crisis, Set to Boost Market Growth of Immunoassays, Concludes Fact.MR

DUBLIN 2, IRELAND - May 6, 2020 - As the number of chronic and infectious diseases compound, medical advancements have grown in equal proportion

Rho Experts Share Regulatory Best Practices on Product Development for the New Coronavirus

RESEARCH TRIANGLE PARK, NC, UNITED STATES - May 5, 2020 -  WHAT:  Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, will outline new information from the Food and Drug Administration (FDA) on the new coronavirus (COVID-19) pandemic as it relates to ongoing and planned clinical research in an upcoming webinar, "Potential COVID-19 Products: Choosing the Right Path with FDA

SEKISUI XenoTech Expands Access to Top-Tier DDI Expertise & Consultancy

KANSAS CITY, KS, UNITED STATES - May 4, 2020 - SEKISUI XenoTech is expanding opportunities for clients to work with top-tier consultants to evaluate drug-drug interaction potential of their drug candidate and bolster their preclinical data package for regulatory submission

CHELSIO AND RYUSSI DEMONSTRATE END-TO-END iWARP RDMA BETWEEN WINDOWS 10 ENTERPRISE AND MoSMB SMB3 SERVER

SUNNYVALE, CALIFORNIA - Feb 12, 2020 - Chelsio Communications, Inc., a leading provider of high performance (1Gb/10Gb/25Gb/40Gb/50Gb/100Gb) Ethernet Unified Wire adapters and ASICs for storage networking, virtualized enterprise datacenters, cloud service installations, and cluster computing environments, and Ryussi America, Inc, a Storage & Systems Product Development and Consulting company, today announced the results of the performance of Chelsio Terminator 6 (T6) iWARP RDMA adapters with Windows 10 Enterprise Client RDMA feature enabling high-speed access to the Ryussi MoSMB SMB3 server using SMB Direct

The New Technology CAR-T Is Expected to Overcome AIDS After Being Transformed

SHIRLEY, NY, UNITED STATES - May 1, 2020 - CAR-T is the short name for Chimeric Antigen Receptor T-Cell Immunotherapy. To put it simply, CAR-T is to transform the patient's immune T cells in vitro to make them recognize the antigens on the surface of tumor cells, and then transfer these cells back to the patient to achieve the therapeutic effect of identifying and killing cancer cells